Strinacin

Quick links to important sections

Strinacin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Strinacin

Property Description
Active Ingredients Trimethoprim, Sulfadiazine
Form Oral Bolus (tablet) or Suspension (liquid)
Pharmacological Class Potentiated Sulfonamide (Antibacterial)
Common Use Treating Systemic Bacterial Infections
Origin Synthetic

Strinacin is a specialized, synthetic antibacterial drug defined as a fixed-dose combination product belonging to the pharmacological class of Potentiated Sulfonamides. This classification is clinically recognized for providing superior antimicrobial activity compared to single-agent sulfonamides. This combination is highly effective in eliminating bacterial growth. Related popular combination brands utilizing this same synergistic formulation include Tribrissen.

The medicine's composition includes two distinct synthetic compounds: Trimethoprim (a diaminopyrimidine) and Sulfadiazine (an intermediate-acting sulfonamide). These components are formulated for the oral route of administration, commonly supplied as a bolus (tablet) or a liquid suspension. It's important to differentiate this systemic agent from the chemically distinct topical preparation, Sulfadiazine Silver, which is used externally for wound care. The specific ratio of Trimethoprim to Sulfadiazine is fixed to ensure optimal synergistic delivery.

The fundamental purpose of Strinacin is to combat and eliminate systemic bacterial infections, a typical use being for complicated urinary or respiratory tract infections. Its unique effectiveness is rooted in its synergistic mode of action, known as sequential blockade. This mechanism targets two consecutive steps in the bacteria's essential process for creating survival materials, ensuring a potent, double-blockage attack on the causative organisms. This reflects the drug's specialized design for decisive antimicrobial action.

Regulatory References

  1. FDA label for Sulfadiazine and Trimethoprim (EQUISUL-SDT)

What side effects are possible with Strinacin?

Possible Side Effects and Safety Information: Strinacin (Trimethoprim/Sulfadiazine)

The safety profile of this potentiated sulfonamide combination is formally structured by regulatory authorities based on clinical data and post-marketing surveillance. This framework describes possible adverse reactions, the organ systems they affect, and specific constraints for use.


Adverse Reaction Classifications

Official documents classify potential adverse reactions across several System-Organ Classes (SOCs). Common effects frequently include Gastrointestinal Disorders (such as nausea, vomiting, and loss of appetite) and Skin and Subcutaneous Tissue Disorders (including rash and urticaria).

However, the label also highlights the documented potential for serious adverse reactions, which are typically rare but clinically significant. These include severe cutaneous events such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as critical Blood and Lymphatic System Disorders, notably agranulocytosis and aplastic anemia. Other serious concerns involve Hepatobiliary Disorders (hepatic necrosis) and Renal and Urinary Disorders (acute renal failure).


Safety Constraints and Population-Specific Notes

Regulatory safety information outlines specific limitations on use. This medicine is contraindicated in certain high-risk groups, including infants under two months of age due to the risk of kernicterus, and individuals with documented severe hepatic damage or severe renal insufficiency when function status cannot be monitored. The label also contains warnings regarding use in patients with pre-existing conditions like folate deficiency (megaloblastic anemia) or G6PD deficiency.

Safety patterns tied to exposure are noted, such as the potential for severe skin reactions to emerge around the start of treatment, and the documented risk of Clostridium difficile-associated diarrhea occurring months after treatment has concluded.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory guidance on Strinacin (Trimethoprim/Sulfadiazine) overdosage focuses on recognizing clinical manifestations and executing mandated emergency actions. Acute overdosage is officially documented to present with gastrointestinal symptoms such as loss of appetite and vomiting. More serious manifestations include CNS effects like confusion and loss of consciousness, as well as signs of systemic toxicity such as blood in the urine and yellowing of the skin or eyes (jaundice).

Mandated Emergency Actions Regulators mandate that immediate medical attention must be sought upon any suspicion of overdosage. The official instruction is to seek emergency medical attention and contact the national Poison Help line immediately. Chronic overexposure, particularly high-dose administration, carries the risk of serious blood disorders, including megaloblastic anemia, and requires specific monitoring.

Official Management and Monitoring Overdose management is defined as symptomatic and supportive. Procedures described in official labeling include gastric lavage, administration of activated charcoal, and forcing oral fluids to promote drug elimination. Because of the risk of blood disorders, frequent complete blood counts (CBC) are mandated for monitoring. The use of folic acid is officially specified to counteract the hematopoietic complications that can arise from chronic trimethoprim overexposure. Patients with severely impaired renal function are noted as being at higher risk due to prolonged drug half-lives.

Therapeutic Uses of Strinacin

Strinacin (Trimethoprim/Sulfadiazine), an antibacterial combination, is used for managing conditions involving susceptible organisms, offering support in addressing symptoms across several key therapeutic domains. The therapeutic scope is commonly used for managing systemic bacterial infections.

This agent is relevant for conditions characterized by periods of heightened symptoms, including complicated and uncomplicated Urinary Tract Infections (UTIs), bacillary dysentery (Shigellosis), bacterial pneumonia, and acute exacerbations of chronic bronchitis. In high-risk situations, it is also utilized for the supportive management and may assist in reducing the risk of opportunistic infections such as Pneumocystis jirovecii Pneumonia (PJP) in immunocompromised patient groups.

The primary benefit relates to the support in managing the infection, which helps with easing acute urological distress and enteric symptoms, as well as symptoms related to systemic imbalance marked by fever and chills. This short-term symptomatic assistance may assist with maintaining functional stability.


Quick Fact: Support for Symptoms Related to Systemic Discomfort

This combination agent is commonly used across conditions presenting with acute episodes where supportive symptom management is appropriate, helping to address symptom clusters that are disruptive, such as fever, dysuria, and acute gastrointestinal distress.

Regulatory References

  1. NIH StatPearls overview on Trimethoprim Sulfamethoxazole

Eligibility and Restrictions for Use

Strinacin (Trimethoprim/Sulfadiazine) eligibility is determined by specific regulatory criteria, establishing both approved and prohibited populations.

Contraindicated Populations (Must Not Use)

  • Individuals with known hypersensitivity to trimethoprim, sulfadiazine, or other sulfonamide derivatives.
  • Infants less than 2 months of age (due to the risk of kernicterus).
  • Patients with severe liver damage or severe chronic kidney disease (creatinine clearance < 15 mL/min).
  • Patients with documented megaloblastic anemia due to folate deficiency, or those with acute porphyria.

Restricted and Conditional Use

  • Pregnancy and Lactation: Use is contraindicated during the first trimester of pregnancy and near term. Use during breastfeeding is prohibited if the infant is jaundiced or G6PD deficient.
  • Age: Use is established for adults and children 2 months of age and older. Older adults require cautious use due to an increased risk of severe adverse reactions.
  • Organ Function: Patients with impaired renal or hepatic function require careful monitoring and restricted dosage or are contraindicated in severe cases.
  • Comorbidities: Caution is required for patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

What should I know about interactions with other medicines?

The interaction profile for Strinacin (Trimethoprim and Sulfadiazine) is defined by official regulatory documentation, which outlines specific restrictions and pharmacokinetic alterations.

Formally Designated Restrictions

Co-administration is contraindicated with certain medications due to a high risk of adverse outcomes. This includes Dofetilide and Clozapine, as explicitly listed in prescribing information. Furthermore, the combination is incompatible with Para-aminobenzoic acid (PABA) and its related esters.

Documented Pharmacokinetic Alterations

Strinacin co-administration can increase the plasma concentration of certain medicines. This effect occurs through inhibited metabolic clearance or reduced renal excretion:

  • Warfarin: Increased anticoagulant effect is documented due to inhibition of its metabolic breakdown.
  • Digoxin: Elevated plasma levels of Digoxin may occur due to inhibited renal secretion.
  • Phenytoin: Inhibition of Phenytoin clearance is documented, leading to increased exposure.

Pharmacodynamic and Population Notes

Interactions resulting from additive physiological effects include an increased risk of severe hyperkalemia when Strinacin is co-administered with ACE Inhibitors or Potassium-Sparing Diuretics. Similarly, the effects of Sulfonylureas may be potentiated, increasing the risk of hypoglycemia. Regulatory documents advise that interaction risks, such as hyperkalemia, are heightened in elderly patients, and caution is required in those with hepatic or renal impairment.

Mechanism of Action

Sequential Blockade of Folic Acid Synthesis

Strinacin works by initiating a dual-step sequential blockade across the bacterial metabolic pathway responsible for synthesizing essential Tetrahydrofolic Acid (THF). The two active components target two distinct, consecutive steps: Sulfadiazine acts first by competitively inhibiting the enzyme Dihydropteroate Synthase (DHPS), and Trimethoprim follows by blocking Dihydrofolate Reductase (DHFR).


Potentiation and Selective Action

This synchronized, dual enzymatic blockade produces a synergistic effect that exceeds the arithmetic sum of the individual component effects. This synergistic action results in a shift in the mechanism of action from bacteriostatic (growth-inhibiting) to bactericidal (cell-killing) for susceptible organisms. Crucially, the mechanism is highly selective, targeting this unique bacterial pathway without significantly interfering with the pre-formed folate utilized by human cells.


Halt of Genetic Material Production

The core physiological consequence of this blockade is the rapid and severe depletion of THF, which is necessary for the synthesis of DNA and RNA building blocks (purines and thymidylate). This molecular starvation immediately halts the bacterial cell’s ability to divide and replicate its genetic material, leading to the cessation of proliferation and death of the bacterial cells.

Dosage and Administration Information

Instruction Map: How to use Strinacin — Administration Guidelines

Strinacin, a fixed-dose potentiated sulfonamide, is intended for oral administration via tablet or suspension. The standard adult regimen for treating systemic bacterial infections is based on a fixed 5:1 ratio of the two active components, corresponding to the equivalent of 160 mg of Trimethoprim per unit dose. This fixed regimen is typically taken every 12 hours (twice daily) to maintain consistent therapeutic levels.


Administration Scope

Field Content
Route of administration Oral (via tablet or liquid suspension).
Dosing schedule The adult standard dose is a fixed 5:1 ratio combination, equivalent to 160 mg Trimethoprim / 800 mg Sulfamethoxazole per unit dose.
Timing in relation to meals May be taken with food or without food.
Preparation requirements Oral suspension formulations require shaking prior to administration; standard tablets require no preparation.
Age-group administration rules Pediatric dosing is calculated separately based on the patient’s body weight (mg/kg).
Special procedural conditions Each dose must be administered with a full glass of water to ensure proper systemic handling and reduce the risk of crystalluria.

Use Protocol and Duration

The total duration of therapy is defined by the specific infection being treated and may vary significantly, ranging from 7 to 14 days for acute urinary tract infections up to 21 days for the treatment of certain opportunistic pneumonias. A dose modification is a mandatory procedural constraint when the user presents with impaired renal function. The protocol establishes a continuous, fixed-dose, twice-daily schedule that governs the precise administration framework and duration of therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Strinacin (Trimethoprim/Sulfadiazine)

Evidence for use in Systemic Bacterial Infections

Research into Strinacin, a potentiated sulfonamide combination, has been studied for its use in managing conditions involving periods of heightened symptoms related to systemic bacterial infections, such as urinary tract infections (UTIs). The available evidence for this use is predominantly based on Randomized Controlled Trials (RCTs) and systematic reviews. Researchers used these studies to compare the combination agent to either a placebo or other standard antibiotic agents.

In these trials, the primary outcomes monitored included measurements of Bacteriological Outcomes (tracking the clearance of causative bacteria) and Clinical Outcomes (tracking the reported change in outcomes related to physical discomfort, such as painful urination). The findings describe patterns observed in the studies regarding the outcomes measured. Research also explored rates of symptom persistence and the frequency of symptom recurrence in the observed patient groups.

The research base for this application is categorized by its consistency and volume of existing data, which is broadly documented as High. However, it is important to note that some foundational evidence originates from older studies. Comparative evidence is lacking for a direct comparison against some of the newest antibiotics developed in recent years.

Evidence for Prophylaxis of Opportunistic Infections

The combination agent was evaluated in a different context: research exploring the agent's use in preventing or managing specific, severe opportunistic infections, such as Pneumocystis Pneumonia, in certain immunocompromised patients. The study designs used here often included systematic reviews and observational cohorts. Researchers primarily examined the overall Mortality and the rate of outcomes related to infection risk when the agent was observed in a long-term preventative role.

What is Still Uncertain About the Research Evidence

Several areas of uncertainty remain documented in the scientific literature. A major gap is the relative lack of contemporary, large-scale RCTs that specifically compare the combination’s performance against the newest antibacterial agents for common infections in general outpatient settings. While evidence contributes to understanding symptom patterns over the short-term, information for long-term outcomes are not fully established when the drug was studied for short-term acute infections. The evidence quality varies across studies, particularly for outcomes monitored, which are often drawn from smaller, observational studies rather than large-scale, dedicated trials.

Key Studies & References

  1. Trimethoprim Sulfamethoxazole (StatPearls/NIH)

Frequently Asked Questions (FAQ)

Common questions about Strinacin (FAQ)

Q: What happens if I miss a day of taking Strinacin?

A: Official guidance for a missed dose is included in the prescribing information. It clarifies the recommended procedure for maintaining the required time interval between doses. This generally means taking the dose as soon as it is remembered, unless it is close to the next scheduled dose time.

Q: Does Strinacin cause weight gain or weight loss?

A: Regulatory documents describe both loss of appetite and weight and weight gain among the reported adverse effects when reviewing possible adverse reactions. These effects are generally classified as being of unknown or rare incidence within the full safety profile.

Q: Can I stop taking Strinacin suddenly, or do I need to taper off?

A: Official instructions emphasize the importance of completing the full, established course of therapy. This helps ensure the infection is fully treated. Discontinuation protocols, including whether or not tapering is needed, are part of the professional prescribing information provided to clinicians.

Q: Is it normal to have [minor, nonspecific symptom, e.g., mild headache] when first using Strinacin?

A: Regulatory safety documents include headache as a possible adverse reaction, though its incidence is considered rare or unknown. Official safety information advises that persisting or concerning symptoms are managed by a healthcare professional.

Q: What is the average duration of treatment with Strinacin?

A: The required total duration of therapy is defined by the specific bacterial infection being treated. For common infections like acute urinary tract infections, the treatment typically ranges from 7 to 14 days. For certain more severe infections, such as opportunistic pneumonias, the course may extend up to 21 days.

Q: Are there any dietary restrictions mentioned in the official Strinacin guidelines?

A: The official restrictions advise that co-administration is incompatible with Para-aminobenzoic acid (PABA) and its related esters, which can sometimes be found in supplements or other products. However, the medicine is generally described as acceptable to take either with food or without food.

Q: How quickly can I expect Strinacin to start working?

A: Pharmacokinetic data from regulatory documents shows the active components reach their peak concentration in the blood approximately 1 to 4 hours after taking an oral dose. Full therapeutic effect, which requires steady-state concentrations, is typically achieved within 2 to 3 days of consistent, scheduled use.

Q: Can Strinacin affect my mood or energy levels?

A: Official safety documents list effects on the central nervous system (CNS) among the possible adverse reactions. These reactions include reports of depression, anxiety, and unusual tiredness or weakness, though their overall incidence is typically rare.

Q: Does Strinacin interact with birth control pills?

A: Authoritative medical reviews indicate that potentiated sulfonamides (like this combination) have generally not been shown to reduce the effectiveness of hormonal contraceptives, such as the birth control pill.

Q: Is Strinacin a narcotic or addictive substance?

A: Strinacin is classified as an antibacterial medication, belonging to the pharmacological class of Potentiated Sulfonamides. It is used to treat bacterial infections and is not classified as a narcotic or a controlled/addictive substance.

Q: Are there different strengths of Strinacin available?

A: The standard adult regimen is a fixed ratio of the two active components (5:1), corresponding to a 160 mg Trimethoprim unit dose. Regulatory information also notes that pediatric dosing is calculated separately based on body weight, implying different available forms or dosage requirements outside of the standard adult dose.

Q: Can Strinacin affect driving or operating machinery?

A: Official safety information for the active components describes possible adverse effects, such as dizziness or unsteadiness. Official safety information notes that these effects may potentially influence the ability to drive or safely operate machinery.

Q: Does the time of day I take Strinacin matter?

A: The regulatory schedule mandates that the fixed dose must be taken every 12 hours (twice daily) to maintain consistent therapeutic levels in the body. The primary goal is adherence to the required 12-hour interval, which is prioritized over taking the dose at a specific time of day (e.g., morning versus evening).

Q: Are there any warnings about Strinacin and heart conditions?

A: Official warnings document that when co-administered with certain blood pressure and heart medications, there is an increased risk of severe hyperkalemia (high potassium levels), which can impact heart function. The label also lists fast heartbeat among possible side effects that have been reported.

Q: Does Strinacin help with [nonspecific symptom related to condition, e.g., pain]?

A: Research studies monitoring the use of this agent focus on clearing the bacterial infection. While clinical outcomes track improvements in physical discomfort (such as painful urination) as the infection resolves, the drug’s function is defined by its antibacterial action, not as a direct pain reliever.

Q: Why is my doctor testing my blood before starting Strinacin?

A: Regulatory safety information advises caution or contraindication in patients who have certain pre-existing conditions. These include impaired renal or hepatic function, or folate deficiency, which are conditions where monitoring via blood testing is advised by regulatory safety information.

Q: Does Strinacin lose its effectiveness over time?

A: The full regulatory safety statement emphasizes the importance of using the medicine only for proven or strongly suspected bacterial infections. This practice is necessary to maintain the drug's effectiveness against susceptible organisms and reduce the development of drug-resistant bacteria.

How should Strinacin be stored and disposed of?

Storage and Disposal Requirements for Strinacin

Official labeling defines specific conditions for storing Strinacin II Tablets to maintain stability. The product must be stored in a dry place and protected from light.


Storage Conditions

  • Temperature: Do not store the product above 25°C.
  • Child Safety: The product must be kept out of reach of children.
  • Stability: The labeled shelf-life of the unopened product is 3 years. Any material dispersed in water for administration must be discarded if not used immediately.

Disposal

Official instructions require that disposal of any unused Strinacin tablets and empty containers be managed in accordance with guidance from your local waste regulation authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Strinacin found in:

A-Z Index: